Endosense, an emerging cardiovascular device com- pany developing the TacticathTM, a unique Force Sensor ablation catheter for use in the field of atrial fibrillation, today announced the appointment of Lawrence Kinet as Chairman of the Board. Mr Kinet was previously a Group Managing Director of Smiths Group PLC and President of Smiths Medical, a major supplier of single-use medical devices used during critical and intensive care procedures with worldwide sales of approximately $1.3 billion.

“I am extremely pleased to welcome Lawrence Kinet as our new Chairman of the Board,” said Eric Le Royer, CEO of Endosense. “Lawrence has an impressive track record in the medical technology field and has demonstrated leadership in both major international com- panies and new ventures. With this appointment, we anticipate that Endosense will benefit considerably from Lawrence’s experience, impressive network and passion for entrepre- neurship.”

Lawrence Kinet has over 30 years of international experience in the field of healthcare services and technology, with a track record of building businesses through profitable sales growth and raising venture and public equity capital, including an IPO. Prior to Smiths Group Plc, Lawrence Kinet was Chairman, President & CEO of Aksys Ltd, a publicly- held medical device company involved in automated home dialysis for kidney patients and Oculon Corp, a specialist in cataract inhibition, respectively. Mr Kinet also held a number of increasingly senior posts at Baxter International Inc. He was Corporate VP & President, World Trade Group, comprising all of Baxter’s operations outside the US, with operating and strategic responsibility for $1.5 billion in sales and 12,000 employees. A United States citizen, Lawrence Kinet obtained his BSc at the University of Birmingham in the UK in 1968 and his MBA at the University of Chicago in 1970.

”During its short history, Endosense has built the right capabilities for executing on a very attractive opportunity. The market for Atrial Fibrillation catheter ablation is estimated to grow to well over $1 billion in the next decade. Endosense has a product that can offer substantial benefits to physicians and patients, making it a sure value for this emerging therapy,” states Kinet. “I am delighted to be part of this high achievement team.”